TABLE 3.

Average values of hormones levels between treated and untreated groups at different time intervals

Time of examination	Treated (n = 463)	Untreated (n = 57)	p value (significant ≤0.05)
FSH (N: 1.5–12.4 mIU/ml)
Before the AAS—courses	6.8 ± 1.1	6.7 ± 1.3	0.8734
At presentation	0.3 ± 0.1	0.3 ± 0.2	1.0000
3 months	0.3 ± 0.2	0.3 ± 0.1	1.0000
6 months	6.4 ± 1.6	0.4 ± 0.1	<0.0001
9 months	5.8 ± 1.8	0.8 ± 0.4	<0.0001
12 months	7.4 ± 2.2	1.2 ± 0.4	<0.0001
LH (N: 1.7–8.6 mIU/ml)
Before the AAS—courses	7.2 ± 1.2	6.9 ± 1.1	0.0730
At presentation	0.3 ± 0.2	0.4 ± 0.2	0.7218
3 months	0.4 ± 0.2	0.3 ± 0.2	0.1322
6 months	5.2 ± 1,2	0.6 ± 0.1	<0.0001
9 months	4.8 ± 2.2	1.0 ± 0.6	<0.0001
12 months	6.4 ± 2.0	1.4 ± 2.0	<0.0001
Testosterone (N: 12–32 nmol/L)
Before the AAS – courses	16.1 ± 1.2	15.8 ± 1.2	0.0755
At presentation	7.0 ± 1.2	7.3 ± 1.0	0.2278
3 months	6.2 ± 2.2	7.1 ± 1.2	1.0000
6 months	12.1 ± 1.2	8.2 ± 1.4	<0.0001
9 months	14.1 ± 2.2	8.6 ± 1.2	<0.0001
12 months	14.4 ± 1.2	9.0 ± 1.0	<0.0001
Estradiol (N: 20–55 pg/ml)
Before the AAS – courses	19.2 ± 0.3	20.1 ± 0.2	0.4340
At presentation	85 ± 1.1	84 ± 1.2	0.1354
3 months	75 ± 1.0	74 ± 1.0	0.1782
6 months	26 ± 1.0	55 ± 2.0	<0.0001
9 months	30 ± 3.0	61 ± 1.0	<0.0001
12 months	24 ± 2.0	55 ± 2.0	<0.0001

Abbreviation: AAS, anabolic androgenic steroid; FSH, follicle‐stimulating hormone; LH, luteinizing hormone.